WTC
LGND icon

WhitTier Trust Company’s Ligand Pharmaceuticals LGND Stock Holding History

WhitTier Trust Company’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.79K Hold
15
– – ﹤0.01% 1176
2026
Q1 		$3.05K Buy
15
+8
+114% +$1.58K ﹤0.01% 1216
2025
Q4 		$1.37K Buy
+7
New +$1.34K ﹤0.01% 1197

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WhitTier Trust Company's LGND Position: Q2 2026 in Review

WhitTier Trust Company held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 15 shares worth $4.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1176.

WhitTier Trust Company first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • WhitTier Trust Company held 15 shares of Ligand Pharmaceuticals worth $4.79K as of Q2 2026.
  • WhitTier Trust Company left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of WhitTier Trust Company's portfolio in Q2 2026, its #1176 holding.
  • WhitTier Trust Company first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.